Dr Alva is a board-certified psychiatrist, a paid consultant of Otsuka America Pharmaceutical, Inc, and Lundbeck, and Mood Disorders Section Editor for Psychiatric Times.
Navigating Major Depressive Disorder (MDD): The Role of Glutamate
Experts discuss the significance of glutamate in major depressive disorder, highlighting its links to neuroplasticity and stress.
Current Challenges With MDD Treatment Options
January 26th 2023Carmen Kosicek, MSN, PMHNP-BC, leads a discussion on the level of satisfaction for both patients and providers with currently available MDD treatment options, barriers to access, and the impact of residual symptoms on a patient’s quality of life.
Role of Telemedicine in Bipolar Disorder
Michael E. Thase, MD; Theresa Cerulli, MD; Gustavo Alva, MD, DFAPA; and Tina Matthews-Hayes, DNP, FNP, PMHNP, provide insight on the role of telemedicine in improving outcomes for patients with bipolar disorder.
Patient Case #2 Continued: Novel Second-Generation Antipsychotics
A panel of experts in psychiatry consider the use of a novel second-generation antipsychotic for the management of treatment resistant depression.
Theresa Cerulli, MD, and Tina Matthew-Hayes, DNP, FNP, PMHNP, review diagnostic difficulties of the patient’s primary care physician in patient case #1 and share optimal approaches to the diagnosis and treatment for patients with bipolar disorder.
Clinical Impressions From Patient Case #1
Tina Matthews-Hayes, DNP, FNP, PMHNP, comments on screening tools for bipolar disorder and Gustavo Alva, MD, DFAPA, shares his impressions from patient case #1.